MHS PHARMACY BENEFIT BONE FORMATION STIMULATING AGENTS PRIOR AUTHORIZATION REQUEST FORM

MHS 550 N. Meridian St. Suite 101 Indianapolis, IN, 46204-1208 Phone: (877) 647-4848 Fax: (866) 399-0929



Today's Date / / / / / / / / / / / / / / / / / / /				
Note: This form must be completed by the preson	cribing provide	r.		
All sections must	be completed	or the request will b	e returned	
Patient's Medicaid #		Date of Birth	/ / /	
Patient's Name		Prescriber's Name		
Prescriber's IN License #		Specialty		
Prescriber's NPI # Prescrib		Prescriber's Signature	rescriber's Signature	
Return Fax #		Return Phone #		
Check box if requesting retroactive PA		Date(s) of service requested for retroactive eligibility (if applicable):		
Note: Submit PA requests for retroactive claims (date timelines) with dates of service prior to 30 calendar a days or less and going forward).				
Requested Medication and Strength	Dosag	e Regimen	Treatment Duration	
PA Requirements for ALL Agents:				
Member has a diagnosis of osteoporosis ☐ Yes ☐ No				
Member is 18 years of age or older ☐ Ye	es 🗆 No			
Select one of the following:				
Select one of the following:	ailed bisphosp	phonate therapy		
☐ Member has previously tried and fa Drug/dose/date(s) of use:	· ·			
☐ Member has previously tried and fa	· ·			
☐ Member has previously tried and fa Drug/dose/date(s) of use:	use of bisphose	sphonate therapy	ated by the World Health	
 ☐ Member has previously tried and fare Drug/dose/date(s) of use: ☐ Member has a contraindication to use ☐ Member has been determined to be 	use of bisphose a high risk party.	sphonate therapy	ated by the World Health	
 □ Member has previously tried and fare Drug/dose/date(s) of use: □ Member has a contraindication to use the Member has been determined to be Organization (WHO) Fracture Risk 	use of bisphose a high risk part Assessment	sphonate therapy patient as demonstr Model		

0423.PH.P.LT 6/23

08.01.2021 Page 1

PA Requirements for FORTEO (preferred):
Does the member have any of the following diagnoses or prior treatments: Paget's disease of bone, prior radiation therapy involving skeleton, bone metastases or skeletal malignancies, metabolic bone disease other
than osteoporosis, pre-existing hypercalcemia (CA++>12mg/dL) $\ \square$ Yes $\ \square$ No
PA Requirements for BONSITY or TERIPARATIDE:
Does the member have any of the following diagnoses or prior treatments: Paget's disease of bone, prior radiation therapy involving skeleton, bone metastases or skeletal malignancies, metabolic bone disease other
than osteoporosis, pre-existing hypercalcemia (CA++>12mg/dL) $\ \square$ Yes $\ \square$ No
Member has tried and failed Forteo ☐ Yes ☐ No Dates of use:
If no , provide medical justification for use over Forteo:
PA Requirements for EVENITY:
Does the member have any of the following diagnoses or prior treatments: Pre-existing hypocalcemia,
myocardial infarction or stroke within the previous year, osteonecrosis of the jaw $\ \square$ Yes $\ \square$ No
Member is a post-menopausal female ☐ Yes ☐ No
Member has tried and failed Forteo ☐ Yes ☐ No Dates of use:
If no , provide medical justification for use over Forteo:
PA Requirements for TYMLOS:
Does the member have any of the following diagnoses or prior treatments: Paget's disease of bone, prior radiation therapy involving skeleton, bone metastases or skeletal malignancies, metabolic bone disease other
than osteoporosis, pre-existing hypercalcemia (CA++>12mg/dL) $\ \Box$ Yes $\ \Box$ No
Member is a post-menopausal female □ Yes □ No
Member has tried and failed Forteo □ Yes □ No Dates of use:
If no , provide medical justification for use over Forteo:

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from MHS, which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.

08.01.2021 Page 2